Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win

Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA). Despite the advancements, there remains unmet need in the indication.